3rd Annual RAS Targeted Drug Development Summit!
Your Comprehensive Roadmap to Developing Next Generation RAS Targeted Therapies 

As 2021 marks a major milestone for RAS therapeutics, with the first ever KRAS targeted therapy receiving FDA approval, the once undruggable RAS family of proteins is no longer impossible to crack. With this significant industry shift, this community will no doubt continue going from strength to strength and the future looks bright for future development of RAS targeted therapies that safely, effectively, and selectively drug all RAS driven cancers beyond those caused by G12C mutation.

The 3rd Annual RAS Targeted Drug Development Summit is returning once again this September to reunite the biggest community of thought leaders and experts in Oncology, Cancer Therapeutics and Clinical Development to discuss robust monotherapies or combination strategies capable of specifically targeting different RAS-mutant cancer cells with less toxicity to enhance the impact of RAS therapies against all RAS driven cancers beyond lung.

Via the latest preclinical, translational and clinical development data-driven case studies from academic and industry pioneers, the 3rd RAS Targeted Drug Development Summit is your only comprehensive roadmap to addressing unique challenges and future directions of finally drugging all RAS mutations and associated targets with novel modalities and next generation combination therapies.

Incorporating tracks taking a deep dive into accelerating emerging modalities, validating robust combination strategies and advancing clinical development, this is your opportunity to gain extensive strategic and scientific information enabling you to solve the exact challenges you’re encountering to support development of safe and effective next generation RAS targeted therapies.

What You Can Expect

RAS 2021 Key Stats

A Snapshot of our 70+ Expert Speaker Faculty

David Hong

Professor, Deputy Chair of the Department of Investigational Cancer Therapeutics

University of Texas M.D. Anderson Cancer Center

Gregory Friberg

Vice President Global Development & Oncology Therapeutic Area Head

Amgen

Marco Hofmann

Scientific Director & Group Leader

Boehringer Ingelheim

Susan Yang

Adagrasib Medical Lead

Mirati Therapeutics

Kathryn C. Arbour

MD, Medical Oncologist

Memorial Sloan Kettering Cancer Center

Mary Smith

Chief Development Officer

SpringWorks Therapeutics

Mollie Leoni

Vice President, Clinical Development

Kura Oncology

Rachel Bond

Research Scientist

SyntheX

Group Discounts Available

Group Discounts - JAK & Innate Immune (12)

Multi-Pass Discount

10% Discount – 3+ Passes
15% Discount – 6+ Passes
20% Discount – 9+ Passes

Other Events In The Undruggable Series